Home News Buy or Sell: Ebix (NASDAQ: EBIX)

Buy or Sell: Ebix (NASDAQ: EBIX)


Ebix trades as part of the application software industry and is in the technology sector. The company CEO is Robin Raina. Ebix Inc provides software and e-commerce solutions to the insurance, finance and healthcare industries.

Previous Intraday Trading Performance:

The EBIX stock showed a previous change of -0.20% with an open at 51.00 and a close of 50.83. It reached an intraday high of 51.28 and a low of 50.43.

SeekingAlpha:  Yatra +38% on Ebix buyout offer


The stock has a market cap of $1.6b with 30.5m shares outstanding, of which the float is 23.3m shares. Trading volume reached 168,556 shares compared to its average volume of 353,231 shares. Based on the current average volume and close price, the trading liquidity is bad, highly speculative and an investor may want to avoid this stock.

Historical Trading Performance:

Over the last five trading days, Ebix shares returned 0.83% and in the past 30 trading days it returned -9.31%. Over three months, it changed 13.35%. In one year it has changed -38.76% and within that year its 52-week high was 89.10 and its 52-week low was 39.27. EBIX stock is 29.44% above its 52 Week Low.

Our calculations show a 200 day moving average of 64.63 and a 50 day moving average of 53.16. Currently EBIX stock is trading -21.36% below its 200 day moving average and may not be a good opportunity to buy as it may continue to trend down.

SeekingAlpha:  Yatra +38% on Ebix buyout offer


The last annual fiscal EPS for the company was reported at 3.73 that ended on 31st of December 2018, which according to the previous close, that is a PE of 17.23. Based on 1 analyst estimate, the estimated EPS for the next quarter is 0.90. The TTM EPS is 3.73, which comes to a TTM PE of 13.63. Historically, the PE high was 28.50 and the PE low was 7.90. If the stock reached its PE low, that would represent a price of 29.46, which is a decrease of -42.04%.

The following are the last four quarter reported earnings per share:
12-31-2018:  1.06
09-30-2018:  0.92
06-30-2018:  0.92
03-31-2018:  0.83

The dividend per share is currently 0.30, which is a dividend yield of 0.59%. Also, the payout ratio is 8.04%, therefore the dividend is safe according to our calculations.

Base on our calculations, the intrinsic value per share is 65.28, which means it is possibly undervalued and has a margin of safety of 22.13%

Indicators to Watch:

Based on the latest filings, there is 126.40% of institutional ownership. Short-interest is 0, which is 0.00% of shares outstanding. The short-interest ratio or days-to-cover ratio is 0.00.

The current calculated beta is 1.60

Business Wire:  Eagle Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2018 Results

Fundamental Indicators:

Based on last reported financials, the company’s return on equity is 19.64%, return on assets is 6.96%, profit margin is 18.77%, price-to-sales is 3.13 and price-to-book is 3.25.

Company Scores:

All scores are out of six:
 5  :Valuation Score
 2  :Past Performance Score
 2  :Financial Strength Score
 4  :Future Growth Score
 0  :Dividend Score
 3  :Overall Score

John Jones
Worked for several Wall Street firms: Salomon Smith Barney, UBS, and Charles Schwab. Has developed skills and gained extensive experience over the years that is used today to uncover winning penny stocks.Also was an attorney for small businesses in Scottsdale, Arizona. That experience and understanding of law provides a unique perspective and edge in discovering quality companies in various industries.